Loading...
Patients who use low-dose aspirin for cardiovascular and neurovascular prophylaxis are at elevated risk for developing peptic ulcers. Famotidine, a histamine-2–receptor antagonist (H2RA), was shown to be more effective than placebo in reducing this risk (JW Gastroenterol Jul 24 2009).
To determine if famotidine is as effective as proton-pump inhibitors (PPIs) in this setting, investigators in Hong Kong conducted a randomized, double-blind, controlled trial involving 160 patients who presented with peptic ulcers or erosions while taking low-dose aspirin (80–320 mg daily).
Patients with Helicobacter pylori infection initially received standard PPI-based triple therapy for 1 week followed by PPI alone for 7 weeks; all other patients initially re…